Bioarctic Ab Class B · OMXSTO:BIOA_B
Bioarctic Ab Class B — Q2 2021 Earnings Presentation
16 slides from Bioarctic Ab Class B's earnings presentation, Jul 9, 2021
Slide 1: Second Quarter Report April-June 2021
BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Second Quarter Report April-June 2021 Stockholm, July 9, 2021 Gunilla Osswald, PhD, CEO Jan Mattsson, CFO BioArctic AB
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: BioArctic – a unique Swedish biopharma company
BioArctic – a unique Swedish biopharma company Improving life for patients with central nervous system disorders High unmet need for disease-modifying treatments for Alzheimer’s and Parkinson’s diseases creates large commercial opportunity World-class research and development driven organization wit
Slide 4: Q2 highlights
Q2 highlights Lecanemab • The FDA granted Breakthrough Therapy designation for lecanemab in Alzheimer’s disease, which is a program intended to facilitate and accelerate the development and review of drugs for serious or life-threatening conditions Other • BioArctic’s manuscript “Elevated soluble am
Slide 5: Our view on current developments in the Alzheimer's disease field
Our view on current developments in the Alzheimer’s disease field 5 BioArctic AB
Slide 6: Attractive and well-balanced project portfolio combines partner and proprietary projects
Attractive and well-balanced project portfolio combines fully- financed partner projects and cutting-edge proprietary projects Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 ALZHEIMER’S DISEASE Lecanemab (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease3 Lecanemab (BAN2401) (AHE
Slide 7: Long-standing and extensive partnerships
Long-standing and extensive partnerships Alzheimer’s disease Parkinson’s disease Partner track record Collaboration and license Partner track record Collaboration and license MEUR 66 MUSD 130 received World’s all-time best-selling received Discovered and developed medicine (BUSD 20) world’s best-sel
Slide 8: Broad lecanemab clinical program – driven by BioArctic's partner Eisai
Broad lecanemab clinical program – driven by BioArctic’s partner Eisai Disease stage Preclinical AD MCI Mild AD Moderate Severe FDA guideline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 AHEAD 3-45 Phase 3 Program – Clarity AD Phase 3 confirmatory ongoing study – ongoing • Eisai and ACTC started
Slide 9: Early-stage portfolio continues to develop well
Early-stage portfolio continues to develop well Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostics Discovery stage Discovery stage Neurodegeneration Brain Transporter (BT) Diagnostics programs projects research • Continued • Continued • Expanded early-stage •
Slide 10: Financial Summary
Financial Summary 10 BioArctic AB
Slide 11: Net revenues and operating profit/loss Q2 2021
Net revenues and operating profit/loss Q2 2021 Net Revenues (MSEK) OPEX by item (MSEK) Operating Profit/Loss (MSEK) 4 60 48 43 42 36 40 38 40 40 32 -11 -21 -21 20 -30 -29 -34 -38 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2019 2020 2021 2019 2020 2021 Project Other external Personnel Deprecia
Slide 12: Cash and net result Q2 2021
Cash and net result Q2 2021 Cash Balance (MSEK) Cash Flow From Operating Net Result (MSEK) 1 170 Activities (MSEK) 4 1 113 1 077 1 050 1 036 1 000 960 930 -9 -8 -20 -13 -27 -29 -17 -21 -36 -38 -29 -49 -34 -54 -38 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2019 2020 2021
Slide 13: Upcoming news and closing remarks
Upcoming news and closing remarks 13 BioArctic AB
Slide 14: Upcoming news flow
Upcoming news flow Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostics Lecanemab (Eisai) ABBV-0805 (AbbVie) Neurodegeneration Brain Transporter (BT) Diagnostics • Data presented at • Complete Phase 1 research technology platform • Continue international and st
Slide 15: BioArctic: With Patients in Mind
BioArctic: With Patients in Mind Great science Great projects Great partners Great people 15 BioArctic AB
Slide 16: Gunilla Osswald, CEO; Jan Mattsson, CFO; Oskar Bosson, VP Communications & IR
GUNILLA OSSWALD, CEO JAN MATTSSON, CFO OSKAR BOSSON, VP NEXT REPORT & IR COMMUNICATIONS & IR CONTACT • Next Report: Q3 2021 Jan-Sept 2021 on October 21, 2021 • Contact: Oskar Bosson, VP Communications & IR +46 704 10 71 80 ir@bioarctic.se To subscribe to financial reports/press releases and for more